Browser Warning
VHBio is not supported on Internet Explorer and will not provide you with the best experience. Please consider switching to a compatible browser such as Microsoft Edge, Google Chrome or Firefox.
We genuinely believe in what we do and want to be the best life sciences supply partner. Any information to help our journey is very welcome. Please take a few minutes to help us improve and make your future experiences better:
Armored Controls have been utilised in IVD-approved assays for more than 20 years and continue to serve as an important tool in the rapidly evolving space of molecular diagnostics. Asuragen’s Armored RNA Quant® (ARQ) technology is preferred for quantitative applications and is constructed by in vitro encapsulation of an in vitro transcribed (IVT) RNA. Armored […]
Armored Controls have been utilised in IVD-approved assays for more than 20 years and continue to serve as an important tool in the rapidly evolving space of molecular diagnostics. Asuragen’s Armored RNA Quant® (ARQ) technology is preferred for quantitative applications and is constructed by in vitro encapsulation of an in vitro transcribed (IVT) RNA. Armored RNA products can be deployed as controls at all stages of a molecular testing workflow from extraction to detection and they serve as a total process control for your molecular assays. They are the most commonly used controls across major commercial molecular infectious disease assays.
The versatile, stable and non-infectious nature of Armored RNA controls renders them usable across all stages of an assay’s lifecycle, from development to routine use in the clinical laboratory.
In response to the worldwide outbreak of COVID-19, Asuragen has developed a novel Armored RNA control that targets the SARS-CoV-2 viral nucleocapsid (N) region. Our new RNAse P construct aligns with the CDC and WHO recommended Diagnostic Panel (CDC-006-00019) providing a stable, reliable, and safe way to rapidly test for the presence of the novel Coronavirus. Each control encodes an in vitro transcribed RNA encapsulated in a protective protein coat to create a virus-like particle resistant to nuclease degradation. This allows the products to be used as RNA extraction controls, process quality controls, or positive diagnostic reference controls. From feasibility to clinical use, these robust and versatile controls are beneficial across all sectors of the research and diagnostic spectrum.
Amplification primer/probe binding regions for SARS-CoV-2 sequences are detailed below. Orange boxes represent the N1 and N2 primer/probe sequences from “CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.” The purple and red boxes indicate primers used for QC of the entire target.
Asuragen Armored RNA Quant Animation from Asuragen on Vimeo.
Product | Volume | Concentration |
---|---|---|
Armoured RNA Quant RNAse P 0652031 |
0.25 mL | 1 x 10¹¹ cp/mL |
Armoured RNA Quant SARS-CoV-2 0652030 |
0.25 mL | 1 x 10¹¹ cp/mL |
Armoured RNA Quant SARS-CoV-2 Panel 0652036 |
0.25 mL | 1 x 10¹¹ cp/mL |
We work with a range of suppliers with novel and innovative products sourced from our global partners.
Find Products